Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Seeks Pediatric Nod for Opdivo in Hodgkin’s Lymphoma
January 29, 2021
- Life Science Institute to Test Muse Cell Therapy in ALS
January 29, 2021
- Ono Apologizes over Arrest of 2 Employees on Bribery Allegations
January 29, 2021
- Forxiga Gets Priority Review Status for CKD in Japan: AZ
January 29, 2021
- SymBio, Univ. of Tokyo Jointly Explore New Indications for Bendamustine, Rigosertib
January 29, 2021
- Sawai Gains Japan Rights for Israeli Firm’s Digital Device for Migraines; Eyes Filing in 2022
January 29, 2021
- Nichi-Iko Puts Mesalazine Supply on Hold over Variations in API Content in Latest Lots
January 29, 2021
- Supply Control for Beova to Last until FY2022: Kyorin/Kissei
January 29, 2021
- Pfizer, Viatris Control Shipment of 9 APIs over Kobayashi Kako, Nichi-Iko Recall Havoc
January 29, 2021
- Bristol Myers Donates 5.5 Billion Yen to Kyoto University to Support I/O Research
January 28, 2021
- Kobayashi Kako Issues Yet Another Recall, Now for 12 APIs/21 Products
January 28, 2021
- MSD’s Anti-MRSA Drug Cubicin Filed for Pediatric Use
January 28, 2021
- Chugai Drops Suit over Edirol Substance Patent, Row Continues for Method-of-Use
January 28, 2021
- BioAge Gets US/Europe Rights for Shionogi’s COVID-19 Treatment
January 27, 2021
- Pfizer’s Methotrexate 1000 mg Hit by Stock-Out on Flaws at German Manufacturing Site
January 27, 2021
- Kenei to Fight Maruho’s Claim over Healmild Trademark to the End
January 27, 2021
- Mitsubishi Tanabe Snaps Up Worldwide Rights for Antibody Drug Candidate for Autoimmune Diseases
January 27, 2021
- Nippon Express’s 3rd Pharma Distribution Hub Launched in Toyama
January 27, 2021
- Chugai’s FoundationOne Approved as CDx for Larotrectinib in Japan
January 26, 2021
- Health Damages Linked to Kobayashi Kako Mix-Up Rise to 215
January 26, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…